Actos (Pioglitazone) Bladder Cancer US
settlementCompany record in this matter
Takeda (Actos) was the named defendant in MDL 2299 (Actos bladder cancer, W.D. La.). The FDA issued a 2011 safety announcement (per FDA) and IARC classified pioglitazone as a Group 1 carcinogen (per IARC, 2011). Takeda reached a $2.4 billion global settlement of ~8,000 claims on April 28, 2015 (per public reports).
Full case record
Court details, case count history, key dates, filings, sources and FAQ are on the main case page:
Frequently asked questions
Is Takeda being sued in Actos (Pioglitazone) Bladder Cancer?
Yes — Takeda is listed among the companies in this matter. Status as of 2026-08-01: settlement. The full case record has the court, docket and all key dates.
What is the status of Actos (Pioglitazone) Bladder Cancer?
As of 2026-08-01, the matter is in the “settlement” stage with 8,000 cases on the record. Every change is logged in the case record's updates section with its source.
Where can I see the full record for Actos (Pioglitazone) Bladder Cancer?
The main case page has the full record: court and judge, case count history, key dates, filings, settlement amounts where published, and sources. It is linked at the top of this section.
About the company
Regulatory history, violations, and every tracked case for Takeda →
Think this matters to you?
This is reference material — not legal advice. Start a free case review.
Start free case review →